Geode Capital Management LLC Purchases 13,038 Shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH)

Geode Capital Management LLC grew its holdings in Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 15.7% during the 4th quarter, Holdings Channel reports. The fund owned 95,946 shares of the company’s stock after buying an additional 13,038 shares during the period. Geode Capital Management LLC’s holdings in Hoth Therapeutics were worth $72,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Virtu Financial LLC bought a new position in shares of Hoth Therapeutics in the third quarter worth approximately $29,000. Hedge funds and other institutional investors own 7.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on HOTH shares. D. Boral Capital reiterated a “buy” rating and issued a $5.00 price target on shares of Hoth Therapeutics in a research note on Tuesday, April 15th. HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Hoth Therapeutics in a research report on Thursday, January 23rd.

Hoth Therapeutics Stock Down 0.3 %

NASDAQ HOTH opened at $0.89 on Monday. Hoth Therapeutics, Inc. has a 52 week low of $0.58 and a 52 week high of $3.80. The company has a fifty day moving average of $0.94 and a two-hundred day moving average of $1.00. The firm has a market capitalization of $11.72 million, a price-to-earnings ratio of -0.67 and a beta of 0.53.

Hoth Therapeutics (NASDAQ:HOTH) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.07. Equities research analysts anticipate that Hoth Therapeutics, Inc. will post -1.36 EPS for the current year.

Hoth Therapeutics Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.